<DOC>
	<DOCNO>NCT00557713</DOCNO>
	<brief_summary>The purpose study determine pathological complete response rate addition bevacizumab induction therapy ( xelox ) concomitant treatment ( capecitabine+radiotherapy ) , follow surgery .</brief_summary>
	<brief_title>XELOX+Bevacizumab Followed Capecitabine+Bevacizumab+Radiotherapy Neoadjuvant Treatment Locally Advanced Rectal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Written inform consent patient able understand study request Histologically confirm diagnosis locally advance rectal adenocarcinoma ; ≤12 cm anal margin ; T3 , operable T4 TxN+ Karnofsky PS Index ≥ 70 % Life expectancy &gt; 6 month Adequate bone marrow , liver renal function : ANC ≥ 1.5 x 10e9/l ; Platelets ≥ 100 x 10e9/l ; Hb ≥ 9g/dl ; INR ≤ 1.5 ; Bilirubin ≤ 1.5 x ULN ; ALT and/or AST ≤ 2.5 x ULN ≤ 5 x ULN ( case hepatic metastasis ) ; Alkaline phosphatase ≤ 2.5 x ULN ≤ 5 x ULN ( case hepatic metastasis ) ≤ 10 x ULN ( case bone metastasis ) ; Creatinine clearance ( CockcroftGault ) ≥ 30 ml/min seric creatinine ≤ 1.5 x ULN Distant metastases ; previous neoplasm last 5 year previous infiltrate neoplasm ; previous treatment radiotherapy study drug ; recruit clinical trial 4 week study entry Surgery , open biopsy traumatic injury 4 week study entry ; fineneedle aspiration 7 day study entry ; major surgery plan study Previous heart disease uncontrolled hypertension , previous hemorrhagic diathesis coagulopathy ; fulldose oral parenteral anticoagulant thrombolytic agent ( lowdose warfarin allow , INR ≤ 1.5 ) ; chronic use highdose aspirin ( &lt; 325mg/day ) nonsteroidal antiinflammatory treatment No integrity upper gastrointestinal tract , malabsorption syndrome unable take oral drug Pregnant lactating patient ; SNC disease ; allogeneic transplant immunosuppressive drug ; bone fracture heal , wound severe ulcer ; uncontrolled intercurrent severe infection ; previous relatedfluoropyrimide SAEs DPD deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>